## Roman Shapovalov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9259597/publications.pdf

Version: 2024-02-01

65 papers

1,097 citations

430874 18 h-index 27 g-index

74 all docs

74 docs citations

times ranked

74

1113 citing authors

#	Article	IF	Citations
1	Correlates of willingness to initiate pre-exposure prophylaxis and anticipation of practicing safer drug- and sex-related behaviors among high-risk drug users on methadone treatment. Drug and Alcohol Dependence, 2017, 173, 107-116.	3.2	57
2	The Pre-exposure Prophylaxis (PrEP) Care Cascade in People Who Inject Drugs: A Systematic Review. AIDS and Behavior, 2021, 25, 1490-1506.	2.7	53
3	Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment. AIDS and Behavior, 2017, 21, 1299-1308.	2.7	52
4	Long-Term Effects of Childhood Risk Factors on Cardiovascular Health During Adulthood. Clinical Medicine Reviews in Vascular Health, 2015, 7, 1-5.	3.0	49
5	Early Sexual Debut: A Risk Factor for STIs/HIV Acquisition Among a Nationally Representative Sample of Adults in Nepal. Journal of Community Health, 2016, 41, 70-77.	3.8	45
6	The Impact of Methadone Maintenance Treatment on HIV Risk Behaviors among High-Risk Injection Drug Users: A Systematic Review. Evidence-based Medicine & Public Health, 2016, 2, .	5.0	43
7	Use of Smartphone to Seek Sexual Health Information Online Among Malaysian Men Who Have Sex with Men (MSM): Implications for mHealth Intervention to Increase HIV Testing and Reduce HIV Risks. Journal of Community Health, 2020, 45, 10-19.	3.8	37
8	The Impact of Methadone Maintenance Treatment on HIV Risk Behaviors among High-Risk Injection Drug Users: A Systematic Review. Evidence-based Medicine & Public Health, 0, 2, .	5.0	36
9	Exploring the Use of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among High-Risk People Who Use Drugs in Treatment. Frontiers in Public Health, 2018, 6, 195.	2.7	33
10	Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors Among Drug Users in Treatment. AIDS and Behavior, 2016, 20, 1646-1657.	2.7	32
11	Examining the Acceptability of mHealth Technology in HIV Prevention Among High-Risk Drug Users in Treatment. AIDS and Behavior, 2017, 21, 3100-3110.	2.7	31
12	A Moderated Mediation Model of HIV-Related Stigma, Depression, and Social Support on Health-Related Quality of Life among Incarcerated Malaysian Men with HIV and Opioid Dependence. AIDS and Behavior, 2017, 21, 1059-1069.	2.7	31
13	Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users. AIDS and Behavior, 2018, 22, 1228-1238.	2.7	31
14	Integrated Bio-behavioral Approach to Improve Adherence to Pre-exposure Prophylaxis and Reduce HIV Risk in People Who Use Drugs: A Pilot Feasibility Study. AIDS and Behavior, 2018, 22, 2640-2649.	2.7	29
15	The Impact of COVID-19 on Access to HIV Prevention Services Among Opioid-Dependent Individuals. Journal of Community Health, 2021, 46, 960-966.	3 <b>.</b> 8	28
16	The Age of Initiation of Drug Use and Sexual Behavior May Influence Subsequent HIV Risk Behavior: A Systematic Review. Isrn Aids, 2013, 2013, 1-17.	2.5	27
17	Developing an Integrated, Brief Biobehavioral HIV Prevention Intervention for High-Risk Drug Users in Treatment: The Process and Outcome of Formative Research. Frontiers in Immunology, 2017, 8, 561.	4.8	25
18	Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs. Journal of Substance Abuse Treatment, 2020, 117, 108058.	2.8	24

#	Article	IF	CITATIONS
19	The Influence of Neurocognitive Impairment on HIV Risk Behaviors and Intervention Outcomes among High-Risk Substance Users: A Systematic Review. Frontiers in Public Health, 2016, 4, 16.	2.7	21
20	COVID-19 Vaccine Hesitancy and Associated Factors among People with HIV in the United States: Findings from a National Survey. Vaccines, 2022, 10, 424.	4.4	21
21	Design and implementation of a factorial randomized controlled trial of methadone maintenance therapy and an evidence-based behavioral intervention for incarcerated people living with HIV and opioid dependence in Malaysia. Contemporary Clinical Trials, 2017, 59, 1-12.	1.8	20
22	The Influence of Neurocognitive Impairment, Depression, and Alcohol Use Disorders on Health-Related Quality of Life among Incarcerated, HIV-Infected, Opioid Dependent Malaysian Men: A Moderated Mediation Analysis. AIDS and Behavior, 2017, 21, 1070-1081.	2.7	19
23	Differential impacts of COVID-19 across racial-ethnic identities in persons with opioid use disorder. Journal of Substance Abuse Treatment, 2021, 129, 108387.	2.8	18
24	An Exploratory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among Participants Enrolled in Methadone Maintenance Therapy. Journal of Substance Abuse Treatment, 2016, 63, 61-65.	2.8	16
25	HIV-Related Stigma, Motivation to Adhere to Antiretroviral Therapy, and Medication Adherence Among HIV-Positive Methadone-Maintained Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 166-173.	2.1	16
26	Treatment Engagement Moderates the Effect of Neurocognitive Impairment on Antiretroviral Therapy Adherence in HIV-Infected Drug Users in Treatment. Journal of the Association of Nurses in AIDS Care, 2017, 28, 85-94.	1.0	15
27	Using individual stated-preferences to optimize HIV self-testing service delivery among men who have sex with men (MSM) in Malaysia: results from a conjoint-based analysis. BMC Public Health, 2020, 20, 1777.	2.9	15
28	Response to the COVID-19 Outbreak in Urban Settings in China. Journal of Urban Health, 2021, 98, 41-52.	3.6	15
29	Sex-Related Differences in Self-Reported Neurocognitive Impairment among High-Risk Cocaine Users in Methadone Maintenance Treatment Program. Substance Abuse: Research and Treatment, 2015, 9, SART.S23332.	0.9	14
30	Interest in use of mHealth technology in HIV prevention and associated factors among high-risk drug users enrolled in methadone maintenance program. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 1144-1148.	1.2	14
31	Viral suppression among HIV-infected methadone-maintained patients: The role of ongoing injection drug use and adherence to antiretroviral therapy (ART). Addictive Behaviors, 2018, 85, 88-93.	3.0	14
32	Cognitive profiles in persons with opioid use disorder enrolled in methadone treatment. Applied Neuropsychology Adult, 2022, 29, 462-468.	1.2	14
33	Association Between Intimate Partner Violence Against Women and HIV-Risk Behaviors. Violence Against Women, 2016, 22, 1621-1641.	1.7	13
34	Willingness to Use HIV Self-Testing and Associated Factors Among Transgender Women in Malaysia. Transgender Health, 2020, 5, 182-190.	2.5	13
35	Mobile Health Technology Use and the Acceptability of an mHealth Platform for HIV Prevention Among Men Who Have Sex With Men in Malaysia: Cross-sectional Respondent-Driven Sampling Survey. Journal of Medical Internet Research, 2022, 24, e36917.	4.3	13
36	<p>Feasibility and Acceptability of an mHealth-Based Approach as an HIV Prevention Strategy Among People Who Use Drugs on Pre-Exposure Prophylaxis</p> . Patient Preference and Adherence, 2020, Volume 14, 107-118.	1.8	12

#	Article	IF	CITATIONS
37	Willingness to initiate pre-exposure prophylaxis (PrEP) and its use among opioid-dependent individuals in drug treatment. Drug and Alcohol Dependence, 2021, 219, 108477.	3.2	11
38	Adapting behavioural interventions to compensate for cognitive dysfunction in persons with opioid use disorder. Annals of General Psychiatry, 2021, 34, e100412.	3.1	10
39	A non-inferiority trial of an evidence-based secondary HIV prevention behavioral intervention compared to an adapted, abbreviated version: Rationale and intervention description. Contemporary Clinical Trials, 2015, 44, 95-102.	1.8	9
40	Intent to Use Preexposure Prophylaxis (PrEP), HIV Risk Behaviors, and Self-Report Neurocognitive Symptoms by High-Risk Drug Users: A Mediation Analysis. Journal of the Association of Nurses in AIDS Care, 2017, 28, 612-621.	1.0	9
41	Willingness to Use Pre-Exposure Prophylaxis (PrEP) for HIV Prevention and PrEP Implementation Preferences Among Transgender Women in Malaysia. Transgender Health, 2020, 5, 258-266.	2.5	9
42	Race, trust, and COVID-19 vaccine hesitancy in people with opioid use disorder Health Psychology, 2022, 41, 115-120.	1.6	9
43	Sex Trafficking Related Knowledge, Awareness, and Attitudes among Adolescent Female Students in Nepal: A Cross-Sectional Study. PLoS ONE, 2015, 10, e0133508.	2.5	8
44	HIV Sero-Status Non-disclosure Among HIV-Infected Opioid-Dependent Individuals: The Roles of HIV-Related Stigma, Risk Behavior, and Social Support. Journal of Community Health, 2019, 44, 112-120.	3.8	8
45	Purposeful Fentanyl Use and Associated Factors among Opioid-Dependent People Who Inject Drugs. Substance Use and Misuse, 2021, 56, 979-987.	1.4	8
46	Privacy and Confidentiality Concerns Related to the Use of mHealth Apps for HIV Prevention Efforts Among Malaysian Men Who Have Sex With Men: Cross-sectional Survey Study. JMIR Formative Research, 2021, 5, e28311.	1.4	8
47	Exploring drivers of pre-exposure prophylaxis uptake among gay, bisexual, and other men who have sex with men in Malaysia. International Journal of STD and AIDS, 0, , 095646242211065.	1.1	8
48	Engagement in Harm Reduction Strategies After Suspected Fentanyl Contamination Among Opioid-Dependent Individuals. Journal of Community Health, 2021, 46, 349-357.	3.8	7
49	Willingness to Be Vaccinated Against COVID-19 Among People With HIV in the United States: Results From a National Survey. Frontiers in Medicine, 0, 9, .	2.6	6
50	Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study. Contemporary Clinical Trials, 2019, 82, 77-84.	1.8	5
51	Online HIV information seeking and pre-exposure prophylaxis awareness among people who use drugs. Journal of Substance Abuse Treatment, 2020, 111, 16-22.	2.8	5
52	Association between the brief inventory of neurocognitive impairment (BINI) and objective cognitive testing among persons with opioid use disorders in drug treatment. Journal of Addictive Diseases, 2021, 39, 166-174.	1.3	5
53	Developing a cognitive dysfunction risk score for use with opioid-dependent persons in drug treatment. Drug and Alcohol Dependence, 2021, 224, 108726.	3.2	5
54	Methadone within prison and linkage to and retention in treatment upon community release for people with opioid use disorder in Kyrgyzstan: Evaluation of a national program. International Journal of Drug Policy, 2022, 101, 103558.	3.3	5

#	Article	IF	CITATIONS
55	Adapting an Evidence-Based HIV Prevention Intervention Targeting High-Risk Migrant Workers: The Process and Outcome of Formative Research. Frontiers in Public Health, 2016, 4, 61.	2.7	2
56	An explanatory factor analysis of a brief self-report scale to detect neurocognitive impairment among HIV-positive men who have sex with men and transgender women in Peru. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 1297-1301.	1.2	2
57	A Self-report Measure to Detect Neurocognitive Impairment Among Incarcerated People Living with HIV in Malaysian Context: an Exploratory Factor Analysis. International Journal of Mental Health and Addiction, 2017, 15, 812-825.	7.4	2
58	Use of Pre-exposure Prophylaxis Among People Who Inject Drugs: Exploratory Findings of the Interaction Between Race, Homelessness, and Trust. AIDS and Behavior, 2021, 25, 3743-3753.	2.7	2
59	Clinical and Demographic Differences in the Willingness to use Self-Administered At-Home COVID-19 Testing Measures among Persons with Opioid use Disorder. Substance Abuse, 2022, 43, 708-712.	2.3	2
60	Latent profile analysis of data from the brief inventory of neurocognitive impairment (BINI) to develop neuro-cognitive profiles among opioid-dependent patients in drug treatment. Journal of Addictive Diseases, 2023, 41, 120-127.	1.3	1
61	PG-12 $\hat{a}$ ef Viral suppression among HIV-infected methadone-maintained patients: The role of ongoing injection drug use and adherence to antiretroviral therapy (ART). Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 77-77.	2.1	0
62	HIV pre-exposure prophylaxis for people who inject drugs. , 2021, , 223-236.		0
63	Limited risk compensation among women who inject drugs. Sexually Transmitted Diseases, 2021, Publish Ahead of Print, .	1.7	0
64	The Use of Female Sex Workers Among Men in Nepal: Prevalence, STIs/HIV-Related Risk Behaviors, and Gender Ideology. Primary Prevention Insights, 2016, 6, 11-17.	1.0	0
65	Influence of Stigma on Pre-Exposure Prophylaxis (PrEP) Care Continuum Among Men and Transwomen Who Have Sex with Men (MTWSM) in the United States. International Journal of HIV/AIDS Prevention Education and Behavioural Science, 2019, 5, 134.	0.1	0